Floatz logo

Rapamycin

Primary Myelofibrosis

OHSU Knight Cancer InstitutePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Primary Myelofibrosis cohort.

Asset / SponsorPhaseRating
Ruxolitinib
OHSU Knight Cancer Institute
Phase 4BBB
Fludarabine
University of Utah
Phase 2BB
TACROLIMUS
City of Hope Medical Center
Phase 2BB
Panobinostat
OHSU Knight Cancer Institute
Phase 4BB
Busulphan
University of Utah
Phase 2B

View all 50 →

Same molecule, other indications

Rapamycin is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →